Home » Health Policy » Pharmaceutical Policy and Regulation (Page 2)

Category Archives: Pharmaceutical Policy and Regulation

Encouraging Integrative, Non-Opioid Approaches To Pain: A Policy Agenda

National initiatives are underway to dramatically reduce access to prescription opioids, but these efforts lack a systematic approach to provide alternative treatments for these patients. Jason Doctor and his colleagues outline three feasible policy initiatives.  (more…)

To Prevent Another EpiPen Controversy, the Government Should Step In

The real problem is with lax regulatory oversight that doesn’t ensure an adequate supply of drugs critical to population health and opens the door to shocking price increases.  (more…)

Can Shopping Around for Prescriptions Save Money?

Research conducted by USC Price MPP students found huge variation in prescription drug prices when shopping around at pharmacies in the LA area.  Based on their experience, they recommend four strategies consumers should use to get the lowest price. (more…)

Finding an Answer to the Hepatitis C Cost Conundrum

We need to shift our treatment strategy to one that treats patients at the optimal time, thereby maximizing the treatment’s effectiveness and controlling costs for payers. (more…)

What the Candidates Don’t Get About Drug Prices

If you are like me, you are watching with relish the presidential debates on both the Republican and Democratic side. Sometimes, amid the reality show-type theatrics, they actually substantive discussions about issues like Social Security, (more…)

A Medication Lock-In Program May Not Be the Easy Solution to the Opioid Abuse Epidemic That Congress Thinks It Is

According to the CDC, in 2010 enough opioid pain relievers were sold to (more…)

For Vulnerable Populations, the Medicare Part D Doughnut Hole Disrupts Medication Adherence

During the annual Medicare Open Enrollment period, senior citizens (more…)

A New Line of Specialty Drugs: PCSK9 Inhibitors (Part 2)

This fall, a new line of specialty drugs will hit the market- PCSK9 inhibitors.  PCSK9 inhibitors are a new class of drugs used to lower LDL (bad) cholesterol levels through stifling a protein (PCSK9). The drug is injected once or twice a month and is (more…)

What’s a Fair Price? The Debate Over Value & Cost of Specialty Drugs (Part 1)

When Turing Pharmaceuticals raised the price of a drug that had been on the market for over 60 years from $13 to $750 a pill there was overwhelming public dismay.  For many, it highlighted the growing concern over prescription drug prices.   (more…)

Vaccine-Preventable Diseases in Adults are Costly

With National Immunization Awareness Month upon us, and the fall respiratory season just around the corner, vaccines are sure to make their way into headlines.  It’s easy to get distracted by the controversy and politicizing that (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook